ArticleVaccine2026
Innovative webinar-based training to support evidence-to-recommendation decision-making by national immunization technical advisory groups: multi-country experience with hexavalent vaccines.
Article in Vaccine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Since endorsement of the Global Vaccine Action Plan, and continued emphasis under Immunization Agenda 2030, the number of functional National Immunization Technical Advisory Groups (NITAGs) has expanded rapidly, creating increased demand for training in evidence-informed decision making. To support timely national policy decisions relating to immunization, innovative and flexible training approaches are needed. This paper describes and evaluates a novel, webinar-based Evidence-to-Recommendation (EtR) training designed to support NITAGs in developing evidence-based recommendations for transitioning from pentavalent plus inactivated polio vaccine to combined hexavalent vaccines. Between January and June 2025, a five-part EtR webinar series focused on the hexavalent vaccine transition was delivered to countries, primarily within the WHO African Region, who qualify to receive financial and technical support from Gavi, the Vaccine Alliance, to help introduce new vaccines and strengthen their immunization systems. The series emphasized identification of evidence across EtR domains, and a cohort-based model to facilitate regional peer learning. Effectiveness of the webinar series was assessed through electronic post-webinar surveys and virtual key informant interviews. NITAGs from 32 countries participated in one or more webinars, including nine in three or more. Across participating countries, participants consistently rated the webinars as useful, particularly valuing country experiences and practical guidance on EtR domains. Qualitative feedback highlighted peer learning as the most valuable component of the webinar series, alongside practice guidance on EtR domains such as feasibility and resource considerations, and NITAGs showed strong interest in continued technical support, practical, peer-to-peer learning or "twinning", and operational guidance for hexavalent vaccine introduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.